Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 19/20 | 1.00 |
| ▸ | CNR1 | P21554 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29387464 | 1.00 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL29410255 | 1.00 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL29858202 | 0.89 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL15478802 | 0.88 | CNR2 (0.79) | CNR2CNR1 | |
| SCHEMBL16201543 | 0.87 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL29358962 | 0.87 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL29989465 | 0.87 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL29019193 | 0.87 | CNR2 (0.77) | CNR2CNR1 | |
| SCHEMBL22678999 | 0.86 | CNR2 (0.75) | CNR2CNR1 | |
| SCHEMBL11983322 | 0.85 | CNR2 (1.00) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186363-A1 | Pharmaceutical Compositions and Methods for Treating Parkinson's Disease | PIKE THERAPEUTICS INC (CA) | 2025-06-12 | — | — | US | disclosed |
| US-12268699-B2 | Transdermal delivery of tetrahydrocannabinol | Pike Therapeutics Inc. (CA) | 2025-04-08 | — | — | US | disclosed |
| US-20250009768-A1 | Transdermal Delivery of Tetrahydrocannabinol | Pike Therapeutics Inc. (CA) | 2025-01-09 | — | — | US | disclosed |
| US-12097293-B2 | Transdermal delivery of cannabidiol | Pike Therapeutics Inc. (CA) | 2024-09-24 | — | — | US | disclosed |
| US-20240024253-A1 | Continuous Drug Delivery Systems and Methods | Pike Therapeutics Inc. (CA) | 2024-01-25 | — | — | US | disclosed |
| EP-4196114-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS OF CANNABINOIDS | Pike Therapeutics, Inc. (CA) | 2023-06-21 | — | — | EP | disclosed |
| US-20230059204-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PHARMACEUTICAL AGENTS | Pike Therapeutics Inc. (CA) | 2023-02-23 | — | — | US | disclosed |
| US-20220347151-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF CHRONIC PAIN | PIKE THERAPEUTICS INC (CA) | 2022-11-03 | — | — | US | disclosed |
| US-20220175718-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF CANCER | PIKE THERAPEUTICS INC (CA) | 2022-06-09 | — | — | US | disclosed |
| WO-2022038479-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS OF CANNABINOIDS | PIKE THERAPEUTICS, INC. (CA) | 2022-02-24 | — | — | WO | disclosed |
| US-20190000802-A1 | DRUG COMBINATION PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USING THEM | VICUS THERAPEUTICS LLC (US) | 2019-01-03 | — | — | US | disclosed |
| US-20180169069-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | VICUS THERAPEUTICS LLC (US) | 2018-06-21 | — | — | US | disclosed |
| US-20170333396-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | VICUS THERAPEUTICS LLC (US) | 2017-11-23 | — | — | US | disclosed |
| US-20160158198-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | VICUS THERAPEUTICS LLC (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160084779-A1 | NUCLEAR MAGNETIC RESONANCE IMPLEMENTED SYNTHETIC INDOLE AND INDAZOLE CANNABINOID DETECTION, IDENTIFICATION, AND QUANTIFICATION | HOFSTRA UNIVERSITY (US) | 2016-03-24 | — | — | US | disclosed |
| EP-2374508-A1 | Combination of angiotension receptor blockers (ARB) and NSAIDs for use in ameliorating cachexia | Vicus Therapeutics SPE 1, LLC (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-2374458-A1 | Combination of an ACE inhibitor and an NSAID for use in ameliorating cachexia/SIRS | Vicus Therapeutics SPE 1, LLC (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20090215852-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | CHROMA GROUP, INC. | 2009-08-27 | — | — | US | disclosed |
| US-20090117197-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | VICUS THERAPEUTICS LLC (US) | 2009-05-07 | — | — | US | disclosed |
| US-20080033027-A1 | Drug combination pharmaceutical compositions and methods for using them | VICUS THERAPEUTICS SPE 1, LLC (US) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12097293-B2 | Transdermal delivery of cannabidiol | CNR2, CNR1, TRPV1 | CNR2 1/4885CNR1 2/4885 |
| US-20220175718-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF CANCER | CNR2, CNR1, DSG1 | CNR2 1/4885CNR1 2/4885 |
| US-20250186363-A1 | Pharmaceutical Compositions and Methods for Treating Parkinson's Disease | PARK7, SNCA, COMT | CNR2 422/4885CNR1 613/4885 |
| US-20220347151-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF CHRONIC PAIN | CNR2, TRPV1, CNR1 | CNR2 1/4885CNR1 3/4885 |
| US-20240024253-A1 | Continuous Drug Delivery Systems and Methods | SMN1; SMN2, PARK7, SNCA | CNR2 45/4885CNR1 81/4885 |
| US-12268699-B2 | Transdermal delivery of tetrahydrocannabinol | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885 |
| US-20250009768-A1 | Transdermal Delivery of Tetrahydrocannabinol | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885 |
| US-20230059204-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PHARMACEUTICAL AGENTS | OPRM1, OPRL1, OPRK1 | CNR2 4/4885CNR1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.